In EDS ansehen

Nudibranch Bioactive Compounds for Anti-Breast Cancer Therapy: A Review and In Silico Studies Targeting ERα and NUDT5.

Gespeichert in:
Bibliographische Detailangaben
Titel: Nudibranch Bioactive Compounds for Anti-Breast Cancer Therapy: A Review and In Silico Studies Targeting ERα and NUDT5.
Autoren: Wulandari, Diah A., Irsal, Riyan A. P., Warsito, Mega F., Habimana, Silas, Nugroho, Aji, Sulistiawati, Septiana, Hidayati, Arlina, Sirait, Putriana S.
Quelle: Tropical Journal of Natural Product Research; Aug2025, Vol. 9 Issue 8, p3455-3464, 10p
Schlagwörter: CANCER cell proliferation, METABOLITES, GENETIC transcription, MOLECULAR docking, BIOACTIVE compounds
Abstract: Marine mollusks, particularly nudibranchs, represent an untapped reservoir of bioactive compounds with significant potential for anti-breast cancer activity. This review consolidates and analyzes the morphology of nudibranchs, their bioactive metabolites, and the molecular mechanisms underlying their Anti-cancer effects. Additionally, it explores the in-silico interactions of nudibranch-derived compounds with two key targets in hormone receptor-positive breast cancer: estrogen receptor alpha (ERα) and nucleoside diphosphate-linked moiety X-type motif 5 (NUDT5). Molecular docking simulations identified ulapualide A as the most promising candidate, exhibiting strong binding affinities and stable interactions with both ERα and NUDT5, surpassing other bioactive compounds. The proposed dual-targeting mechanism of ulapualide A involves competitive inhibition of ERα by blocking estrogen binding, preventing receptor dimerization and nuclear translocation, thereby reducing the transcription of pro-cancer genes. Simultaneously, ulapualide A inhibits NUDT5 activity, which is essential for disrupting nuclear ATP production and depleting the energy supply required for ERα-driven transcription. Thus, this dual inhibition strategy represents a synergetic approach to suppressing breast cancer cell proliferation. Although the in-silico results are promising, additional in-vitro and in-vivo studies are essential to validate the therapeutic efficacy and safety of ulapualide A. This study underscores the potential of marine-derived compounds, particularly nudibranch metabolites, as promising candidates for targeted breast cancer therapy development and as a new avenue for oncology discovery. [ABSTRACT FROM AUTHOR]
Copyright of Tropical Journal of Natural Product Research is the property of University of Benin, Faculty of Pharmacy and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Datenbank: Biomedical Index
Beschreibung
Abstract:Marine mollusks, particularly nudibranchs, represent an untapped reservoir of bioactive compounds with significant potential for anti-breast cancer activity. This review consolidates and analyzes the morphology of nudibranchs, their bioactive metabolites, and the molecular mechanisms underlying their Anti-cancer effects. Additionally, it explores the in-silico interactions of nudibranch-derived compounds with two key targets in hormone receptor-positive breast cancer: estrogen receptor alpha (ERα) and nucleoside diphosphate-linked moiety X-type motif 5 (NUDT5). Molecular docking simulations identified ulapualide A as the most promising candidate, exhibiting strong binding affinities and stable interactions with both ERα and NUDT5, surpassing other bioactive compounds. The proposed dual-targeting mechanism of ulapualide A involves competitive inhibition of ERα by blocking estrogen binding, preventing receptor dimerization and nuclear translocation, thereby reducing the transcription of pro-cancer genes. Simultaneously, ulapualide A inhibits NUDT5 activity, which is essential for disrupting nuclear ATP production and depleting the energy supply required for ERα-driven transcription. Thus, this dual inhibition strategy represents a synergetic approach to suppressing breast cancer cell proliferation. Although the in-silico results are promising, additional in-vitro and in-vivo studies are essential to validate the therapeutic efficacy and safety of ulapualide A. This study underscores the potential of marine-derived compounds, particularly nudibranch metabolites, as promising candidates for targeted breast cancer therapy development and as a new avenue for oncology discovery. [ABSTRACT FROM AUTHOR]
ISSN:26160684
DOI:10.26538/tjnpr/v9i8.3